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INTRODUCTION:
The goals of this grant are to determine if the NF-B pathway is active in the basal-like breast cancer subtype and in Her2+ breast cancer (a new extension of the previous aims) and if this pathway can be targeted by small molecule inhibitor s in a man ner that is therapeutic. Patients wit h basal-like breast ca ncer and wit h Her2+ breast can cer typically e xhibit poor outcomes, thus new th erapies are required [refs. 1 -5] . Our evidence is that a set of genes, known to be regulated by NF-B, i s upregulat ed in basal-like tumors and, interestingly, in cell lines that are basal-like. Some of t he basal-like cell lines exhibit phosphorylated IKK, a ke y upstream regulator of the NF-B pathway [6] . The NF-B pathway is k nown to be involved in oncogenesis, but it s role in basa l-like breast cancer is u nclear [refs. 7, 8] . Animal models o f basal-like br east cancer also exhibit upregulation of some of these N F-B-dependent gene s (our data). Additionally, we have found that NF-B is activated by Her2 (an EGFR family member that is upregulated in approximately 25% of breast cancer), although expression of NFkB-dependent genes is not identical between th e two types of breast cancer. Our g oals are to analyze basal-like cell lines, human tumors, and anima l models of ba sal-like can cer to furthe r validate our hypothesis that NF-B is active in these tumors and may, therefore, represent a new therapeutic target for this brea st cancer subtype with poor prognosis. Similar approaches will be performed on Her2+ breast cancer.
Aims
of th e proposal are to: ( i) analyze extracts of human breast can cer for phosphorylated IKK an d other ma rkers of NF-B activati on. Determine if these markers correlate with expression of Bcl2 A1 and oth er NF-B-dependent g enes., (ii) d etermine the mechanism of activation of Bcl2A1 and other NF-B-dependent genes in basal-like cancer cells, and compare this mechanism with pathways operativ e in distinct bre ast cancer subtypes (i.e., Her2+ cells. Thus a new addition to the aims is to analyze Her2+ breast tumors and cell lines to analyze a role for NF-B in this cancer, and to d etermine how NF-B is activated in these cells. Analyze inhibitors of the NF-B pat hway for effects on gro wth and sur vival of basal-like, a nd Her2+ breast cancer cells. (iii). Analyze experimental tumors for markers outlined in A ims 1 and 2. Using animal mode ls represent ative of basal-like and Her2 brea st cancer, determine if inhibitors analyzed in Ai m 2 will sup press growth of the tumors, and/or sensitize the tumors to chemotherapy. Additionally, we have added 2 new aims (as part of an extended statement of work -we will determine (i) if Parp1 is a reg ulator of N F-B in basal-like and other breast cancers and, if so, determine if Parp 1 inhibitors suppress growth/survival of these cancer cells and (ii) analyze tumor i nitiating cells from brea st cancer ce ll lines and experimental tumors for the activation of NF-B.
BODY (end of 2 nd year report):
Regarding Aim 1 goals:
--(as noted in the last report) we ha ve analyzed extracts of a number of breast tumors (7). We detected phosphorylated p65/RelA in samples 3, 4, 5, 6, an d 7 (see Fig. 1 ). Bcl2A1 expression was found in tumor samples 2, 4 and 5. Tumors 2 and 4 are basal-like and 5 is luminal A/IIE subset (a t umor subtype that is known to express Bcl2A 1). Thus, t hese result s show that phospho-p65 ser536 is not dire ctly correlated with Bcl2A 1 expressio n, but that Bcl2A1 is expressed in 2/2 basal-like tumors (consiste nt with our hypo thesis) but not in Her2+, luminal B, or luminal A (not IIE subtype). We are now testing a larger number of tumor samples.
Regarding Aim 2 goals:
--(as noted in the last report) we have performe d analysis of basal-like breast cancer cell lines and found t he upregulation of the NF-B subu nit c-Rel (se e Figs. 2 an d 3 ). cRel is known to regulate Bcl2A1 in other cells. We a re testing a larger numb er of tumors, and animal tumors, to expand this study.
--we performed analysis of Her2+ breast can cer cell line s which indicates t hat p65/RelA i s phosphorylated, and tha t certain NF-B-dependent genes a re upregulat ed. Note th at Bcl2A 1 was not fou nd in the H er2+ breast cancer cell lines, suggesting that either a diff erent NF-B subunit is involved in control of Bcl2A1 expression in ba sal-like can cer, or that a differe nt cofactor is involved. IKK and IKK  are both i mportant in controlling g ene expression and in activating NF-B in these cells. IKK drives invasion of these cells (these studies are published - Merkhofer et al., 2010 -see ref. 10 , and see attached).
--(as noted previously) treatment of basal-like breast cancer cell lines with the Bayer IKK  inhibitor reduces expression of the associated NF-B-dependent gene set and ind uces growth arrest (see Table 1 below). Note that another g roup has now published that NF-B is important for growth/p roliferation of basal-like cells (Yamaguchi et al., 2009) . T his may preclude our ability to pu blish the se results alo ne, but we are looking a t other aspe cts to in clude in a new publication.
--In order to analyze tumor initiatin g cells from breast tumor cell lines and from murine breast tumors, we have cultured these cells and have shown that they form mammospheres (consistent with a stem-cell like component) (see Fig. 4 ).
Regarding Aim 3 goals, we have: --Crossed the RelA fl/fl animal with Her2+ animals, along wit h expression of cre recombinase in the breast. This will test the role of the p65/RelA subunit in progression of Her2+ breast cancer.
--We are breeding the C3Tag animals for analysis Regarding new aim of analyzing Parp1 inhibitor:
--(preliminary data -ju st performed once) we have shown that Parp 1 inhibitor blocks NF-kB activation in basal-like cancer cells.
Regarding new direction of analyzing tumor iniating cells: --We have isolated pre viously characterized tu mor initiatin g cells from basal-like and Her2+ breast can cer cell lin es and from a primary Her2+ animal tumor, and ha ve shown mammasphere growth (indicative of the presence of tumor initiating cells -see Fig. 4 
below).

KEY RESEARCH ACCOMPLISHMENTS:
--Contrasted Her2+ positive breast cancer cells with basal-like cells, indicating differ ential gene expression (Merkhofer et al., 2010 ; see attached).
--Demonstrated that IKK and NF-B promote invasion in Her2+ breast cancer cells (Merkhofer et al., 2010 ).
--Treatment of basal-like breast cancer cells with an IKK inhibitor suppresses expression of the NF-B-dependent gene set and induces growth arrest/apoptosis.
--Treatment of Her2+ breast cancer cells with the NBD peptide (an inhibitor of total IKK activity) suppressed growth/survival (described in Merkhofer et al., 2010) .
REPORTABLE OUTCOMES:
--Manuscript published r egarding studies on He r2+ breast cancer cells and the involvement of IKK/NF-B in controlling gene expression and invasion. This study provides interesting parallels and differences with basal-like cancer.
--Evidence that c-Rel is upregulated in basal-like breast cancer cell lines.
CONCLUSIONS:
Both basal-like breast cance r cells and Her2+ brea st cancer cells exhibit activation of NF-kB, but the genes that are regulated in these cells b y NF-B ap pear to be different. Analysis of human breast tumor e xtracts confirms prediction that Bcl2A1 is active in basal-like cancers and in the luminal A IIE group. Analysis of basal-like breast cancer cell lines indicates that c-Rel is upregulated in these cells, which is a potential link with control of Bcl2A1 gene expression. Comparison of Her2+ breast cancer cells with basal-like cells indicates that NF-B is active in both t ypes of breast cancer. We have begun the pro posed therapy studies in the model for basal-like cancer, using an IKK inhibitor which shows growth suppressive activity on basal-like breast cancer cell lines.
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6.
Using Her2
þ /ER À breast cancer cells, we show that Her2 activates NF-jB through the canonical pathway which, surprisingly, involves IKKa. Knockdown of IKKa led to a significant decrease in transcription levels of multiple NF-jB-regulated cytokine and chemokine genes. siRNAmediated knockdown of IKKa resulted in a decrease in cancer cell invasion, but had no effect on cell proliferation.
Introduction
The epidermal growth factor receptor Her2 is amplified in 20-30% of breast cancers, which typically do not express estrogen receptor, and are often correlated with poor prognosis and/or chemoresistance, making Her2 an important therapeutic target (Slamon et al., 1987 (Slamon et al., , 1989 Hynes and Stern, 1994; Klapper et al., 2000) . The Her2-specific antibody trastuzumab and the dual EGFR/Her2 inhibitor lapatinib have been shown to decrease growth of Her2-overexpressing tumors (Pegram et al., 1998; Baselga et al., 1999) ; however, a majority of patients treated with trastuzamab develop resistance (Slamon et al., 2001) , indicating the importance of elucidating alternative therapeutic targets in this disease. Her2-overexpression was first shown to activate NF-kB over a decade ago (Galang et al., 1996) , however, the role that NF-kB has in development and progression of Her2-overexpressing breast cancer is still poorly understood. In addition, the pathway leading to NF-kB activation downstream of Her2 is not well characterized.
NF-kB is an important transcription factor that has been shown to be involved in expression of genes involved in key cellular processes including innate and adaptive immunity (Bonizzi and Karin, 2004) , cell proliferation and survival (Papa et al., 2006) , lymphoid organ development (Weih and Caamano, 2003) , as well as being activated in a variety of different cancers, including breast cancer (Cogswell et al., 2000; Basseres and Baldwin, 2006; Belguise and Sonenshein, 2007) . The NF-kB family of transcription factors consists of five subunits: RelA (p65), RelB, c-Rel, p105/p50 and p100/p52. These subunits are evolutionarily conserved and exist as hetero-or homodimers (Hayden and Ghosh, 2004) . The p65/p50 heterodimer is the most abundant NF-kB complex in the cell and is regulated by the so-called canonical pathway. Following stimulation with activators such as TNF, IkB is phosphorylated by the inhibitor of kappaB kinase (IKK) complex. The IKK complex consists of two catalytic subunits IKKa, and IKKb, and a regulatory subunit IKKg (NEMO), which binds both catalytic subunits at their NEMO-binding domain (Gilmore, 2006) . In the canonical pathway, IKKb phosphorylates IkBa leading to its degradation and NF-kB nuclear accumulation (Ghosh and Karin, 2002) . Furthermore, the p65 subunit of NF-kB can be phosphorylated on multiple residues, including serine 536, which is important for transactivation potential (Sakurai et al., 1999) . NF-kB activation can also occur via the alternative, or non-canonical pathway. Activation of NF-kB in the non-canonical pathway, most common in B cells, involves IKKa and is IkBaindependent (Solt and May, 2008) . Thus most current models place IKKb as the dominant IKK subunit in the canonical pathway with IKKa functioning in the noncanonical system. Few studies have addressed the individual roles of IKKa and IKKb downstream of oncoprotein-dependent signaling.
Using an siRNA approach, we set out to determine how NF-kB is activated downstream of Her2, and what role the IKK complex has in this signaling cascade, as well as how the activation of the IKK kinases may lead to a malignant state. Although the classical pathway has long been thought to require IKKb, here we show that IKKa has a larger role than IKKb in the activation of NF-kB in Her2 þ breast cancer cells, including the phosphorylation of the p65 subunit at serine 536. Using siRNA to the IKK kinases, we show that knockdown of IKKa leads to a change in the gene expression profile in Her2 þ cells, including a notable cytokine and chemokine gene expression signature. Furthermore, knockdown of IKKa by siRNA led to a marked decrease in invasive ability in SKBr3 cells, yet had no effect on cell proliferation. Taken together, our data suggests that Her2 can activate NF-kB through the canonical pathway. Surprisingly, this activation occurs primarily through IKKa, a subunit typically not thought to be involved in the canonical pathway. Interestingly, we have discovered differential roles for the IKK kinases with IKKa specifically involved in an invasive oncogenic phenotype in Her2 þ breast cancer cells.
Results
Lapatinib inhibits Her2 activation of NF-kB and Akt
It has previously been shown that Her2-overexpression leads to activation of NF-kB family members involved in the canonical pathway, specifically the p65/p50 heterodimeric complex (Galang et al., 1996; Biswas et al., 2004) . Given this result, we investigated whether the dual EGFR/Her2 inhibitor Lapatinib (Tykerb, GW572016) could block Her2-induced p65 phosphorylation at serine 536, a marker of increased NF-kB transcriptional activity (Sakurai et al., 1999) . Five breast cancer cell lines were treated with 1 mM lapatinib for 12 h and whole-cell extracts were analysed for expression of phosphorylated p65. A marked decrease in p65 phosphorylation was observed in Her2-ovexpressing tumor cell lines (SKBr3 and MDA-MB-453) upon treatment with lapatinib, whereas non-Her2-overexpressing tumor cell lines (MCF7 and MDA-MB-231) showed no change ( Figure 1a) . The H16N2-Her2 cell line also showed a decrease in p65 phosphorylation upon lapatinib treatment. Overexpression of Her2 in this cell line results in NF-kB activation, as the parental cell line, H16N2-pTP, has very little basal p65 phosphorylation (Supplementary Figure 1 ). To further investigate how Her2 signals to NF-kB, we chose to use the tumor-derived SKBr3 cell line, as it has previously proven to be an excellent in vitro model for Her2 þ /ER À breast cancer (Singh et al., 2007) . SKBr3 cells were treated with 1 mM lapatinib or vehicle control over a course of 24 h and whole-cell extracts were analysed for levels of phosphorylated IkBa. Phosphorylation of IkBa at serines 32 and 36 was inhibited within 3 h of lapatinib treatment (Figure 1b) . Stabilization of IkBa was also observed, consistent with the loss of phosphorylated IkBa. It has previously been shown that Her2-overexpression activates the PI3K/Akt pathway and that lapatinib can inhibit Akt phosphorylation in lapatinib-sensitive Her2 overexpressing breast cancer cell lines (Hegde et al., 2007) . Similarly, we observe a decrease in phosphorylation of Akt at serine 473 in the lapatinib-sensitive SKBr3 cell line upon treatment with lapatinib ( Figure 1c ). This indicates that Her2 can activate both the NF-kB and the PI3K/Akt pathways, and that pharmacological inhibition of Her2 leads to subsequent inhibition of these survival pathways. Table 1 ). Genes that showed significant changes in expression upon siRNA transfection were validated by quantitative real-time PCR. Decrease in expression of pro-inflammatory cytokines and chemokines IL-6, IL-8, CCL-2, TNF and the serine-protease uPA, was greater upon siRNA knockdown of IKKa than IKKb in both SKBr3 and H16N2-Her2 breast cancer cell lines (Figure 3a) . To show that IKKdependent changes in gene expression were occurring through modulation of NF-kB transcriptional activity, we performed RNAi against the classic subunit p65 in SKBr3 and H16N2-Her2 cells and assayed expression of mRNA by quantitative real-time PCR. Gene expression analysis showed that knockdown of p65 by siRNA led to a significant decrease in gene transcription levels of IL-8, IL-6, TNF and uPA (Figure 3b ). This transcriptional profile mirrors that seen upon knockdown of IKK, specifically IKKa, suggesting that induction of chemokines and cytokines in Her2 breast cancer cells occurs through IKK activation of p65. We next measured changes in expression of these genes in SKBr3 cells following treatment with lapatinib to confirm this activation of NF-kB-regulated genes was induced downstream of overexpression of Her2. Treatment of SKBr3 cells with 1 mM of lapatinib led to a significant decrease in gene expression of IL-6, IL-8, CCL-2, TNF and uPA at both 8 and 16 h post treatment (Figure 3c ). Taken together, this suggests that Her2 activates NF-kB through the canonical pathway involving IKKa and leading to an increase in multiple NF-kB-regulated genes involved in tumor progression.
Activation of NF-kB in Her2-overexpressing cells requires NEMO
The scaffolding subunit of the IKK complex, IKKg (NEMO), is required for activation of NF-kB canonical pathway involving IKKb (Gilmore, 2006) , and inhibition of the IKK signalsome with the Nemo-binding domain peptide can block NF-kB activation (Biswas et al., 2004) . We used an siRNA approach to determine the importance of NEMO in NF-kB activation in Her2-overexpressing cell lines. siRNA knockdown of NEMO led to a marked decrease in p65 phosphorylation in all three Her2 þ cell lines (Figure 4a ). NF-kB luciferase reporter activity was also significantly decreased in these cell lines upon siRNA knockdown of NEMO (Figure 4b ). We performed quantitative real-time PCR analysis in the SKBr3 cell line upon NEMO knockdown to determine if this resulted in a similar gene expression profile as IKKa knockdown. Consequently, IL-6, IL-8, TNF and CCL2 all showed a significant decrease in expression upon NEMO knockdown, though uPA expression levels did not change (Figure 4c ). To rule out any effect loss of IKKa could have on non-classical activation of NF-kB, we analysed processing of the p100 subunit. Cleavage of the precursor NF-kB protein p100 to p52 is a hallmark of activation of the non-canonical pathway. No significant effect was seen on p100 processing to p52 upon knockdown of either of the IKK subunits in Her2 þ cells (Figure 4d ). These results suggest that NF-kB activation in Her2 þ cells occurs through IKKa and this requires the NEMO subunit. In addition, these results indicate that the non-canonical NF-kB-signaling pathway is not activated in Her2 þ breast cancer cells.
Activation of the NF-kB canonical pathway is independent of the PI3K pathway It was reported earlier that expression of dominantnegative PI3K and Akt plasmids can block NF-kB DNA binding downstream of Her2 (Pianetti et al., 2001) . Therefore, we investigated if NF-kB activation downstream of Her2 is dependent on the PI3K/Akt pathway. Upon treatment of SKBr3 cells with lapatinib, phosphorylation of Akt at Serine 473 decreases dramatically (Figure 1a) . Treatment with the PI3K inhibitor LY294002 also blocked phosphorylation of Akt at serine 473, however, LY294002 had no effect on the phosphorylation status of p65 at serine 536 in SKBr3, H16N2-Her2 or MDA-MB-453 cells (Figures 5a-c) . Furthermore, treatment of SKBr3 cells stably expressing the 3 Â kB luciferase reporter with LY294002 had no Her2 activation of NF-jB through IKKa EC Merkhofer et al effect on NF-kB transcriptional activity (Figure 5d ). These results show that Her2 activates Akt through PI3K, and that the Her2-induced activation of NF-kB is independent of this pathway.
IKKa induces cell invasion but not cell proliferation
Having determined that overexpression of Her2 leads to IKKa-dependent activation of the NF-kB classical pathway, we next sought to determine how this signaling may promote oncogenic phenotypes. We investigated the effect IKK activation may have on proliferation of Her2-overexpressing breast cancer cells. SKBr3 cells were transfected with siRNA to the IKK catalytic subunits and cell proliferation was measured by MTS assay. Knockdown of IKKa or IKKb had no inhibitory effect on cell proliferation (Figure 6a) . As a control, SKBr3 cells were treated with the PI3K-inhibitor LY294002, as well as lapatinib. Inhibition of PI3K/ Akt or Her2 led to a dramatic decrease in cell growth (Figure 6b) , consistent with what has been previously reported, suggesting that Her2 drives cell proliferation through the PI3K/Akt pathway. Our previous results have shown IKK/NF-kB dependent increases in proinflammatory cytokines downstream of Her2, and these genes have been shown to promote increased motility and invasiveness. Furthermore, overexpression of Her2 has been shown to lead to increase in invasiveness of breast cancer cells (Arora et al., 2008) . We reasoned that NF-kB activity downstream of Her2 may contribute to increased invasiveness of Her2 breast cancer. To address this question, SKBr3 cells were transfected with siRNA to IKKa and IKKb and the ability of the cells to invade through a basement membrane was measured. Knockdown of IKKa led to a significant decrease in invasiveness of SKBr3 cells while knockdown of IKKb had no effect (Figure 6c ). This suggests that Her2 overexpression results in the activation of at least two independent oncogenic signaling pathways, one involving PI3K/Akt and another involving NF-kB, which have two different but important roles in promoting tumorigenesis (Figure 6d ). 
Her2 activation of NF-jB through IKKa
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Discussion
Although Her2-positive breast cancer is known to activate both NF-kB and PI3K/Akt pathways, (Pianetti et al., 2001; Knuefermann et al., 2003; Biswas et al., 2004; She et al., 2008) , it has been unclear how Her2 induces NF-kB and whether PI3K is involved with this pathway. In addition, potential roles for IKKa and IKKb in controlling Her2-induced NF-kB have not been addressed. The latter point is of interest because IKKa and IKKb have previously been associated with controlling distinct NF-kB pathways, with IKKb controlling the so-called canonical pathway and IKKa controlling the non-canonical pathway. These issues are potentially quite important in the therapeutic setting. Our data indicate the following: (i) IKKa has an important role in controlling the ability of Her2 to activate NF-kB through the canonical pathway (including phosphorylation of IkBa, phosphorylation of RelA/p65, activation of IKK and regulation of gene expression), (ii) IKKa controls the invasion of Her2 þ cells, with apparently little contribution of IKKb in this process and (iii) PI3K-dependent pathways do not contribute to the direct activation of NF-kB in these cells. Previous experiments from several groups have shown that IKKb has a major role in controlling canonical NF-kB activation downstream of inflammatory cytokines such as TNF (Verma et al., 1995) . The potential contribution of IKKa to NF-kB activation downstream of Her2-dependent signaling or to that induced by other oncoproteins has not been fully elucidated. Lapatinib has been shown to be effective in its inhibition of the Akt and Erk pathways in Her2 overexpressing breast cancer cell lines and human tumor xenografts, but there are no reports of it having an effect on the NF-kB pathway (Xia et al., 2002; Zhou et al., 2004) , although Herceptin has been shown to inhibit NF-kB activation þ cell lines were transfected with 100 nM NEMO siRNA and whole-cell extracts were prepared 72 h post-siRNA transfection and luciferase levels were measured. Fold change of reporter activity with IKK knockdown is shown relative to scrambled siRNA-treated cells. Values are the average of at least three experiments. Error bars are ±1 s.e. Samples are normalized by protein concentration (SKBr3) or renilla (H16N2-Her2 and MDA-MB-453). (c) SKBr3 cells were transfected with 100 nM NEMO siRNA and extracts were isolated after 72 h and qRT-PCR was performed. Fold change of transcript levels is shown relative to scrambled siRNA-treated cells. Error bars are ± 1 s.e. (d) Her2-overexpressing breast cancer cells were transfected with 100 nM siRNA to IKKa or IKKb and whole-cell extracts were collected 72 h post transfection. Levels of p100 and p52 were measured by western blot analysis using 25 mg of total protein. (Biswas et al., 2004) . In our studies, treatment of Her2-overexpressing cell lines with 1 mM lapatinib led to a marked decrease in phosphorylation of NF-kB subunit p65 at serine 536 and of IkBa at serines 32 and 36 (Figures 1a and b) . Lapatinib also blocked NF-kB-induced gene transcription (Figure 3c ). Treatment of SKBr3 cells with lapatinib led to complete loss of phosphorylation of Akt at serine 473 (Figure 1c) , a marker for Akt activation.
Her2 activation of NF-jB through IKKa
To address potential contributions of IKKa and IKKb to NF-kB activation in Her2 þ cells and to the oncogenic phenotype, we used an IKK knockdown approach in Her2-overexpressing cells. Knockdown of IKKa led to a more dramatic reduction in p65 phosphorylation at Ser536 than did knockdown of IKKb (Figure 2a) . Furthermore, knockdown of IKKa strongly reduced NF-kB activation as measured through electrophoretic mobility shift assay and NF-kB-dependent reporter assays, whereas IKKb knockdown had less of an effect (Figures 2b and c) . Similarly, knockdown of IKKa was more effective at blocking IKK activity than knockdown of IKKb (Figure 2d ). SKBr3 cells show low levels of p52/NF-kB2, which is derived from IKKa-dependent processing of the p100/NF-kB2 precursor. Knockdown of IKKa had little effect on p52 levels in these cells, indicating that the non-canonical pathway does not appear to be active in SKBr3 cells at a measurable level. Consistent with this, very low to undetectable levels of p52 or RelB are detected in the nuclei of SKBr3 cells (data not shown). It is important to note that inhibition of IKKb can lead to a compensatory response whereby IKKa controls canonical NF-kB activation in some cell types (Lam et al., 2008) . Our studies clearly indicate that loss of IKKa leads to reduced NF-kB activation downstream of Her2-induced signaling. A study showing that IKKa is necessary for self-renewal of Her2-transformed mammary-initiating tumor cells (Cao et al., 2007) is consistent with our results showing the importance of IKKa in controlling NF-kB downstream of Her2. The way in which Her2 may selectively activate IKKa in breast cancer remains to be investigated. One possibility is selective activation of IKKa by the kinase NIK, as NIK has been shown to associate with ErbB2 family member EGFR (Habib et al., 2001) and has been shown to be recruited to EGF/heregulin receptor-signaling complexes (Chen et al., 2003) .
The knockdown studies were extended to analysis of NF-kB-dependent target gene expression (Figure 3a) . Knockdown of IKKa lead to a more dramatic reduction in gene expression of IL-6, IL-8, CCL2, TNF and uPA than did knockdown of IKKb. Decreased expression of these genes upon knockdown of the p65 subunit of NF-kB indicates that this activation is occurring through the canonical pathway (Figure 3b ). To show that these genes are controlled through Her2, and not through Her2-independent pathways, lapatinib was shown to block target gene expression (Figure 3c ). This increase in chemokine and cytokine gene expression by Her2, as well as the increase in the expression of the 
EC Merkhofer et al serine protease uPA, shows a large similarity to Her2-induced gene expression signatures, which have been previously reported, and this increase has been implicated in progression of multiple different cancers, including breast cancer (Wang et al., 1999; Arihiro et al., 2000; Chavey et al., 2007; Vazquez-Martin et al., 2008) . Therefore, our gene expression data suggests that IKKa has an important role in regulating genes involved in breast cancer progression, and this requires the scaffolding subunit NEMO (Figure 4 ). Some studies indicate that NF-kB can be activated downstream of PI3K/Akt (Makino et al., 2004; Dan et al., 2008) . However, experiments using the PI3K inhibitor LY294002 indicate that NF-kB is not activated in Her2 þ cells downstream of PI3K ( Figure 5 ). Thus, this pathway is not a link between Her2, IKKa and NF-kB activation. We cannot rule out a PI3K-independent Akt-controlled pathway in NF-kB activation. In addition, we cannot rule out that PI3K and/or Akt have effects on NF-kB-target gene expression that function separately from the induction of NF-kB activation as assayed through experiments described above. Future studies will address Her2-regulated pathways that lead to activation of IKK. Other studies (Dillon et al., 2007) as well as our own (Figure 6b) show that activation of the PI3K pathway has an important role in cell proliferation/viability. Interestingly, knockdown of IKKa or IKKb subunits (individually or together) by siRNA has no measurable inhibitory effect on cell proliferation (Figure 6a ).
To determine if IKKa or IKKb controls other oncogenic phenotypes, we used siRNA treatment and measured cell invasion of SKBr3 cells. Her2 overexpression has been shown to induce cell invasion, consistent with its ability to promote upregulation of genes such as IL-8 and uPA (Gum et al., 1995; VazquezMartin et al., 2008) . Knockdown of IKKa, but not knockdown of IKKb, significantly blocks the invasive phenotype of SKBr3 cells (Figure 6c ). This result is consistent with the regulation of target genes by IKKa that are associated with invasive phenotype. Interestingly, other factors have linked breast cancer invasion and NF-kB, including microRNAs (Ma et al., 2007) . MicroRNAs have been shown to negatively regulate NF-kB activity and gene expression, such as micro-RNA-146, which can suppress expression of IL-6 and IL-8 through a reduction in levels of IRAK1 and TRAF6 in MDA-MB-231 cells, leading to the metastatic phenotype (Bhaumik et al., 2008) .
This study shows that Her2 activation of NF-kB requires IKKa, and this PI3K-independent activation leads to an increase in cytokine and chemokine ) and IkBa from Cell Signaling Technology (Beverly, MA, USA); antibodies against Her2, IKKa clone 14A231 and IKKb clone10AG2 and p100/p52 from Millipore (Billerica, MA, USA), antibodies against p65 and p50 (supershift), b-tubulin and IKKg from Santa Cruz Biotechnology (Santa Cruz, CA, USA), antibody against total p65 from Rockland (Gilbertsville, PA, USA) LY294002 and Wortmannin were purchased from Cell Signaling Technology. Lapatinib (GW572016; Tykerb, GSK, Brentford, Middlesex, UK) was a gift from Dr H Shelton Earp (University of North Carolina at Chapel Hill).
Immunoblots
Whole-cell extracts were prepared on ice with Mammalian Protein Extraction Reagent (Thermo Scientific, Waltham, MA, USA) according to the manufacturer's instructions supplemented with protease inhibitor mix (Roche) and phosphatase inhibitor mix (Sigma). Nuclear and cytoplasmic extracts were prepared as previously described (Mayo et al., 1997) . Protein concentrations were determined by Bradford assay (Biorad Laboratories, Hercules, CA, USA) and SDS-PAGE analysis was performed as previously described (Steinbrecher et al., 2005) .
Small RNA interference
The following small interfering RNAs (siRNA; siGenome SMARTpool) were obtained from Dharmacon (Lafayette, CO, USA) as a pool of four annealed double-stranded RNA oligonucleotides: IKKa (M-003473-02), IKKb (M-003503-03), NEMO (M-003767-02), RelA (p65) (M-003533-02) and non-targeting control no. 3 (D001201-03). Cells were grown to approximately 50% confluency and transfected with 100 nmol/l siRNA with Dharmafect 1 reagent according to the manufacturer's instructions.
Quantitative real-time PCR Total RNA extracts were obtained from cells approximately 72 h post-transfection by Trizol (Invitrogen) extraction. Two micrograms of RNA were reverse transcribed using random primers and MMLV-reverse transcriptase (Invitrogen). Real-time PCR was performed and analysed as previously described (Steinbrecher et al., 2005) using Taqman Gene Expression Assay primer-probe sets IL-6 (Hs00174131_m1), IL-8 (Hs001741103_m1), CCL2 (Hs00234140_m1), TNF (Hs99999043_m1) and uPA (Hs00170182_m1).
Electrophoretic mobility shift assay Electrophoretic mobility shift assay and NF-kB supershift analysis were done on nuclear extracts as previously described (Steinbrecher et al., 2005) using 32 P-labeled oligonucleotide probe corresponding to an NF-kB site within the MHC class I promoter region.
IKK kinase assay
Whole-cell lysates were prepared on ice for 45 min in lysis buffer containing 20 mmol/l Tris (pH 8.0), 500 mmol/l NaCl, 0.25% Triton X-100, 1 mmol/l EDTA, 1 mmol/l EGTA, 1 mmol/l DTT, 1 Â protease inhibitor (Roche Applied Science) and 1 Â phosphatase inhibitor cocktail (Sigma-Aldrich). IKK complexes were immunoprecipitated from 500 mg total protein extract using IKKg antibody (Santa Cruz Biotechnology). An in vitro kinase assay was done and analysed as previously described (Steinbrecher et al., 2005) using GST-IkBa as a substrate.
Luciferase assay SKBr3 cells stably expressing the 3 Â kB plasmid were plated in equal number in triplicate in 24-well plates and transfected with siRNA for 72 h or treated overnight with LY294002. Cells were lysed in MPER and luciferase activity was measured with Promega Luciferase Assay System (Promega, Madison, WI, USA). Luciferase levels were normalized by protein concentration using a Bradford assay. H16N2-Her2 and MDA-MB-453 cells were transfected with siRNA 72 h before lysates were obtained, and were transfected with 3 Â kB reporter plasmid and pRL-CMV (Promega) renilla plasmid 24 h before lysate collection. Lysates were collected as mentioned above and luciferase levels were normalized to renilla.
Cell invasion assay
Innocyte Cell Invasion Assay Kit was purchased from Calbiochem (San Diego, California, CA, USA). Cells were transfected with siRNA for 48 h before seeding. Invasion assay was performed as per the manufacturer's protocol for 48 h. The number of invading cells was measured fluorometrically with Calcein AM.
Cell proliferation assay
Cell proliferation assay was performed as previously described (Wilson and Baldwin, 2008) . Cells were cultured in the presence or absence of inhibitors, or transiently transfected Her2 activation of NF-jB through IKKa EC Merkhofer et al
